Heron Therapeutics (HRTX) Misses Q1 EPS by 15c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Heron Therapeutics Announces Financial Results for the Three Months Ended March 31, 2022 and Highlights Recent Corporate Updates
May 9, 2022 4:05 PM EDT- ZYNRELEF® unit demand increased 68% in the first quarter compared to the prior quarter -
- Centers for Medicare and Medicaid Services approved a 3-year transitional pass-through status for ZYNRELEF beginning April 1, 2022 to support separate reimbursement outside of the surgical bundle payment for the HOPD setting of care -
-Â Oncology Care Franchise net revenue of $22.4 million in Q1 2022, a 13% increase over the prior quarter -
- Oncology Care Franchise full-year 2022 net revenue expected to be $89 million to $93 million... More
